aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
ALX Oncology Holdings Inc., founded by industry veterans in South San Francisco, California, is a clinical-stage immuno-oncology company. Its core mission is to transform cancer treatment by developing evorpacept, a first-in-class foundational checkpoint immunotherapy. The company focuses on creating therapies that block CD47, a protein that cancer cells use to evade the immune system. ALX Oncology aims to maximize clinical activity while minimizing toxicities, targeting various oncology indications such as myelodysplastic syndromes, acute myeloid leukemia, and several types of carcinoma.
Notable affiliated people include its founding team of industry veterans with extensive experience in oncology and biotech. The company has attracted significant investment from leading venture capital firms specializing in life sciences. Key achievements include advancing evorpacept through clinical trials and demonstrating promising efficacy and safety profiles. ALX Oncology's innovative approach has the potential to significantly impact cancer treatment paradigms, offering new hope for patients with difficult-to-treat cancers.
Operating Status
Active
Ownership Type(s)
Public
Main Product(s)
Cancer Therapies
Technology
Biotech
Tags
Healthtech
Model Types
Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
United States
When was ALX Oncology Holdings founded?
ALX Oncology Holdings was founded in 2020.
Where is ALX Oncology Holdings’s headquarters located?
ALX Oncology Holdings’s headquarters is located in South San Francisco, CA, US.
How many employees does ALX Oncology Holdings have?
ALX Oncology Holdings has 71 employees as of Feb 6, 2024.
Add Comparison
Total Employees Over Time
71
As of Feb 2024
ALX Oncology Holdings Address
323 Allerton Av
South San Francisco,
California
94080
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts